CalcMyPeptide
Growth HormoneAlso known as: NN703, NNC 26-0161

Tabimorelin

Tabimorelin stands as a massively potent, orally active Growth Hormone Secretagogue (GHS) that pushed deep into Phase II clinical trials for severe adult GH deficiency. Operating as a highly engineered, true peptide-mimetic, it successfully breached the gastric barrier without requiring injection. While ultimately shelved by pharma in favor of highly profitable recombinant HGH, it remains a testament to elite secretagogue engineering designed to maximize natural pulsatile release.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Low

Quick Stats

Half-Life~3 hours
Dose Range0.5-10 mg/day (oral)
Frequency1× daily (oral)
Vial SizesN/A (oral)
BioavailabilityOral
Year Developed1990s

Scientific Data

Molecular Formula
C32H39N5O4
Molecular Weight
557.7 g/mol
CAS Number
PubChem ID
Developer

Mechanism of Action

Tabimorelin (NN703) is a synthetic, orally active non-peptide growth hormone secretagogue (GHS). Like Ibutamoren (MK-677), it was designed to mimic ghrelin and bind to the ghrelin receptor (GHS-R1a) to stimulate a powerful, pulsatile release of naturally occurring human growth hormone (HGH) and IGF-1 from the pituitary gland.

It was developed as a potential oral treatment for age-related growth hormone deficiency (somatopause) and frailty. While it effectively raises IGF-1 levels, it holds lower affinity than MK-677 and development was largely paused in clinical trial phases.

Source: PMID: 11401563

Background & History

Tabimorelin (NN703) was developed by Novo Nordisk as a potential oral alternative to GH injections for growth hormone deficient adults. It entered Phase II clinical trials in the early 2000s showing dose-dependent GH elevation, but the magnitude of IGF-1 increase and clinical endpoints were modest compared to established GH replacement therapy. Development was discontinued, but tabimorelin remains an important reference compound in the growth hormone secretagogue field.

Research Use Cases

  • GH deficiency research
  • Oral GH secretagogue development
  • GHS-R1a pharmacology research

Dosing Protocol

Typical Dose0.5-10 mg/day (oral)
Frequency1× daily (oral)
Half-Life~2 hours

Dosing Protocols

Research / Clinical Trials

Dose
Oral capsule
Frequency
Daily
Note: Abandoned in clinical trials. Replaced functionally in research/market by the more potent Ibutamoren (MK-677).

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 50010000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)386 mcg4050 mcg7714 mcg
140 lb(63 kg)450 mcg4725 mcg9000 mcg
160 lb(73 kg)521 mcg5475 mcg10429 mcg
180 lb(82 kg)586 mcg6150 mcg11714 mcg
200 lb(91 kg)650 mcg6825 mcg13000 mcg
220 lb(100 kg)714 mcg7500 mcg14286 mcg
250 lb(113 kg)807 mcg8475 mcg16143 mcg

💉 For exact syringe units based on your vial concentration, use the Tabimorelin Reconstitution Calculator →

Administration

Route
Oral
Timing
N/A
Fasting Required?
No — food timing not critical

Expected Timeline

Acute
Stimulates large pulse of systemic HGH and IGF-1.

Who Is It For?

Growth Hormone Secretagogue

Low

Historical interest; essentially a lesser-known, discontinued analogue conceptually identical to MK-677.

Safety & Considerations

Not FDA approved. Like all ghrelin mimetics, likely induces severe hunger and temporary insulin resistance.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

May increase cortisol and prolactin transiently. Similar drug interaction profile to other ghrelin mimetics — caution with insulin-sensitizing agents due to potential GH-mediated insulin resistance.

Synergies & Common Stacks

Both are oral GHS-R1a agonists. MK-677 is a non-peptide while tabimorelin is a peptide-mimetic — useful for comparing structural class effects on GH secretion patterns.

Tabimorelin and GHRP-2 share the GHS-R1a mechanism. Comparing oral (tabimorelin) vs injectable (GHRP-2) routes.

Dosing Quick Reference

Tabimorelin— Dosing Guide
Dose Range
0.5-10 mg/day (oral)
Half-Life
~2 hours
Frequency
1× daily (oral)
Route
Oral
Growth Hormonecalcmypeptide.com

Frequently Asked Questions

Is Tabimorelin a peptide?
No, like MK-677, it is a non-peptide chemical developed to mimic a peptide (ghrelin) while maintaining high oral bioavailability.

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code